Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Moos, M' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 79 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Mehlig, M; Moos, M; Braun, V; Kalt, B; Mahony, DE; von Eichel-Streiber, C
      Variant toxin B and a functional toxin A produced by Clostridium difficileC34

      FEMS MICROBIOLOGY LETTERS
    2. Lipinski, E; Cremer, FW; Ho, AD; Goldschmidt, H; Moos, M
      Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation

      BONE MARROW TRANSPLANTATION
    3. Cremer, FW; Goldschmidt, H; Moos, M
      Clonotypic B cells in the peripheral blood of patients with multiple myeloma

      BLOOD
    4. Braun, V; Mehlig, M; Moos, M; Rupnik, M; Kalt, B; Mahony, DE; von Eichel-Streiber, C
      A chimeric ribozyme in Clostridium difficile combines features of group I introns and insertion elements

      MOLECULAR MICROBIOLOGY
    5. Cremer, FW; Ehrbrecht, E; Kiel, K; Benner, A; Hegenbart, U; Ho, AD; Goldschmidt, H; Moos, M
      Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma

      BONE MARROW TRANSPLANTATION
    6. Moos, M; von Eichel-Streiber, C
      Purification and evaluation of large clostridial cytotoxins that inhibit small GTPases of Rho and Ras subfamilies

      REGULATORS AND EFFECTORS OF SMALL GTPASES, PT D
    7. Voso, MT; Pantel, G; Weis, M; Schmidt, P; Martin, S; Moos, M; Ho, AD; Haas, R; Hohaus, S
      In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma

      BRITISH JOURNAL OF HAEMATOLOGY
    8. Bellos, F; Goldschmidt, H; Dorner, M; Ho, AD; Moos, M
      Bone marrow derived dendritic cells from patients with multiple myeloma cultured with three distinct protocols do not bear Kaposi's sarcoma associated herpesvirus DNA

      ANNALS OF ONCOLOGY
    9. Johnson, PWM; Swinbank, K; MacLennan, S; Colomer, D; Debuire, B; Diss, T; Gabert, J; Gupta, RK; Haynes, A; Kneba, M; Lee, MS; Macintyre, E; Mensink, E; Moos, M; Morgan, GJ; Neri, A; Johnson, A; Reato, G; Salles, G; van 't Veer, MB; Zehnder, JL; Zucca, E; Selby, PJ; Cotter, FE
      Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study

      ANNALS OF ONCOLOGY
    10. Nolte, C; Moos, M; Schachner, M
      Immunolocalization of the neural cell adhesion molecule L1 in epithelia ofrodents

      CELL AND TISSUE RESEARCH
    11. Kiel, K; Cremer, FW; Rottenburger, C; Kallmeyer, C; Ehrbrecht, E; Atzberger, A; Hegenbart, U; Goldschmidt, H; Moos, M
      Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation

      BONE MARROW TRANSPLANTATION
    12. Muller, S; von Eichel-Streiber, C; Moos, M
      Impact of amino acids 22-27 of Rho-subfamily GTPases on glucosylation by the large clostridial cytotoxins TcsL-1522, TcdB-1470 and TcdB-8864

      EUROPEAN JOURNAL OF BIOCHEMISTRY
    13. Voso, MT; Hohaus, S; Moos, M; Pforsich, M; Cremer, FW; Schlenk, RF; Martin, S; Hegenbart, U; Goldschmidt, H; Haas, R
      Autografting with CD34(+) peripheral blood stem cells: retained engraftment capability and reduced tumour cell content

      BRITISH JOURNAL OF HAEMATOLOGY
    14. Moos, M
      Dear Readers

      ALTEX-ALTERNATIVEN ZU TIEREXPERIMENTEN
    15. Moos, M; Schulz, R; Martin, S; Benner, A; Haas, R
      The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma

      LEUKEMIA
    16. von Eichel-Streiber, C; Weidmann, M; Giry, M; Moos, M
      Activation and inactivation of Ras-like GTPases by bacterial cytotoxins

      METHODS IN MICROBIOLOGY, VOL 27
    17. KALLMEYER C; WALLMEIER M; KIEL K; MOOS M; HEGENBART U; HAAS R; GOLDSCHMIDT H
      DECREASED NUMBERS OF CIRCULATING B-CELLS IN MYELOMA PATIENTS WITH REDUCTION AFTER CONVENTIONAL CHEMOTHERAPY

      American journal of hematology
    18. CREMER FW; KIEL K; WALLMEIER M; HAAS R; GOLDSCHMIDT H; MOOS M
      LEUKAPHERESIS PRODUCTS IN MULTIPLE-MYELOMA - LOWER TUMOR LOAD AFTER MOBILIZATION WITH CYCLOPHOSPHAMIDE PLUS GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) COMPARED WITH G-CSF ALONE

      Experimental hematology
    19. KIEL K; CREMER FW; EHRBRECHT E; WALLMEIER M; HEGENBART U; GOLDSCHMIDT H; MOOS M
      FIRST AND 2ND APHERESIS IN PATIENTS WITH MULTIPLE-MYELOMA - NO DIFFERENCES IN TUMOR LOAD AND HEMATOPOIETIC STEM-CELL YIELD

      Bone marrow transplantation
    20. MOOS M; SCHULZ R; MUREA S; HAAS R
      DURATION OF T(14-18) PCR-NEGATIVITY AS PROGNOSTIC PARAMETER IN PATIENTS WITH FOLLICULAR NON-HODGKINS-LYMPHOMA UNDERGOING HIGH-DOSE THERAPY WITH PERIPHERAL-BLOOD STEM-CELL SUPPORT

      Bone marrow transplantation
    21. KIEL K; CREMER FW; EHRBRECHT E; GOLDSCHMIDT H; MOOS M
      FIRST AND 2ND APHERESIS IN PATIENTS WITH MULTIPLE-MYELOMA - NO DIFFERENCES IN TUMOR LOAD AND HEMATOPOIETIC STEM-CELL YIELD

      Bone marrow transplantation
    22. CREMER FW; KIEL K; WALLMEIER M; HAAS R; GOLDSCHMIDT H; MOOS M
      LEUKAPHERESIS PRODUCTS (LP) IN MULTIPLE-MYELOMA - LOWER TUMOR LOAD AFTER MOBILIZATION WITH CYCLOPHOSPHAMIDE (CY) PLUS G-CSF COMPARED TO G-CSF ALONE

      Bone marrow transplantation
    23. FLORESDIAZ M; ALAPEGIRON A; TITBALL RW; MOOS M; GUILLOUARD I; COLE S; HOWELLS AM; VONEICHELSTREIBER C; FLORIN I; THELESTAM M
      UDP-GLUCOSE DEFICIENCY CAUSES HYPERSENSITIVITY TO THE CYTOTOXIC EFFECT OF CLOSTRIDIUM-PERFRINGENS PHOSPHOLIPASE-C

      The Journal of biological chemistry
    24. GOLDSCHMIDT H; HEGENBART U; CREMER FW; KIEL K; MOOS M
      PERIPHERAL-BLOOD STEM-CELL MOBILIZATION IN MULTIPLE-MYELOMA (MM) - HIGH-DOSE CYCLOPHOSPHAMIDE PLUS G-CSF VS. G-CSF ALONE

      British Journal of Haematology
    25. KIEL K; CREMER FW; EHRBRECHT E; WALLMEIER M; GOLDSCHMIDT H; MOOS M
      FIRST AND 2ND APHERESIS IN PATIENTS WITH MULTIPLE-MYELOMA - NO DIFFERENCES IN TUMOR LOAD AND HEMATOPOIETIC STEM-CELL YIELD

      British Journal of Haematology
    26. Bellos, F; Cremer, FW; Ehrbrecht, E; Goldschmidt, H; Moos, M
      Leukapheresis cells of patients with multiple myeloma collected after mobilization with chemotherapy and G-CSF do not bear Kaposi's sarcoma associated herpesvirus DNA

      BRITISH JOURNAL OF HAEMATOLOGY
    27. CREMER FW; KIEL K; WALLMEIER M; GOLDSCHMIDT H; MOOS M
      A QUANTITATIVE PCR ASSAY FOR THE DETECTION OF LOW AMOUNTS OF MALIGNANT-CELLS IN MULTIPLE-MYELOMA

      Annals of oncology
    28. GOLDSCHMIDT H; HEGENBART U; WALLMEIER M; MOOS M; HAAS R
      HIGH-DOSE CHEMOTHERAPY IN MULTIPLE-MYELOMA

      Leukemia
    29. CREMER FW; KIEL K; SUCKER C; WACKER J; ATZBERGER A; HAAS R; GOLDSCHMIDT H; MOOS M
      A RATIONALE FOR POSITIVE SELECTION OF PERIPHERAL-BLOOD STEM-CELLS IN MULTIPLE-MYELOMA - HIGHLY PURIFIED CD34(-FRACTIONS OF LEUKAPHERESIS PRODUCTS DO NOT CONTAIN MALIGNANT-CELLS() CELL)

      Leukemia
    30. WAGENKNECHTWIESNER A; WEIDMANN M; BRAUN V; LEUKEL P; MOOS M; VONEICHELSTREIBER C
      DELINEATION OF THE CATALYTIC DOMAIN OF CLOSTRIDIUM-DIFFICILE TOXIN B-10463 TO AN ENZYMATICALLY ACTIVE N-TERMINAL-467 AMINO-ACID FRAGMENT

      FEMS microbiology letters
    31. MUREA S; MOOS M; VOSO MT; HOHAUS S; GOLDSCHMIDT H; WANNENMACHER M; HAAS R
      HIGH-DOSE THERAPY WITH PERIPHERAL-BLOOD STEM-CELL (PBSC) TRANSPLANTATION IN PATIENTS WITH INDOLENT NON-HODGKINS-LYMPHOMAS (NHL)

      Experimental hematology
    32. WANG SW; KRINKS M; LIN KM; LUYTEN FP; MOOS M
      FRZB, A SECRETED PROTEIN EXPRESSED IN THE SPEMANN ORGANIZER, BINDS AND INHIBITS WNT-8

      Cell
    33. LIN KM; WANG SW; JULIUS MA; KITAJEWSKI J; MOOS M; LUYTEN FP
      THE CYSTEINE-RICH FRIZZLED DOMAIN OF FRZB-1 IS REQUIRED AND SUFFICIENT FOR MODULATION OF WNT SIGNALING

      Proceedings of the National Academy of Sciences of the United Statesof America
    34. FLORESDIAZ M; ALAPEGIRON A; PERSSON B; POLLESELLO P; MOOS M; VONEICHELSTREIBER C; THELESTAM M; FLORIN I
      CELLULAR UDP-GLUCOSE DEFICIENCY CAUSED BY A SINGLE-POINT MUTATION IN THE UDP-GLUCOSE PYROPHOSPHORYLASE GENE

      The Journal of biological chemistry
    35. MOOS M; SCHMOHL D; BOTZ D; FISCHER K; SCHLENK R; DOHNER H
      PROSPECTIVE MONITORING OF MINIMAL RESIDUAL DISEASE BY POLYMERASE CHAIN-REACTION IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA EXPRESSING CBF-BETAMYH11 FUSION TRANSCRIPTS/

      Blood
    36. KIEL K; CREMER FW; EHRBRECHT E; ATZBERGER A; KALLMEYER C; GOLDSCHMIDT H; MOOS M
      CIRCULATING TUMOR-CELLS IN PATIENTS WITH MULTIPLE-MYELOMA PRIOR TO AND POST HIGH-DOSE THERAPY AND PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION

      Blood
    37. KIEL K; CREMER FW; EHRBRECHT E; WALLMEIER M; GOLDSCHMIDT H; MOOS M
      FIRST AND 2ND APHERESIS IN PATIENTS WITH MULTIPLE-MYELOMA - NO DIFFERENCES IN TUMOR LOAD AND HEMATOPOIETIC STEM-CELL YIELD

      Blood
    38. MOOS M; SCHULZ R; MUREA S; GOLDSCHMIDT H; HAAS R
      MONITORING OF MINIMAL DISEASE IN PATIENTS WITH FOLLICULAR NON-HODGKINS-LYMPHOMA UNDERGOING HIGH-DOSE THERAPY WITH PERIPHERAL-BLOOD STEM-CELL SUPPORT

      Blood
    39. SCHLENK R; HARTMANN F; MOOS M; PFORSICH M; FISCHER K; BENNER A; FISCHER JT; WEBER W; GUNZER U; PRALLE H; HAAS R; DOHNER H
      SUCCESSFUL COLLECTION OF PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC) IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA (AML) FOLLOWING ONE OR 2 CYCLES OF CONSOLIDATION THERAPY WITH GRANULOCYTE-COLONY-STIMULATING FACTOR-SUPPORTED HIGH-DOSE CYTARABINE AND MITOXANTRONE (HAM)

      Blood
    40. CREMER FW; KIEL K; WALLMEIER M; HAAS R; GOLDSCHMIDT H; MOOS M
      LEUKAPHERESIS PRODUCTS IN MULTIPLE-MYELOMA - LOWER TUMOR LOAD AFTER MOBILIZATION WITH CYCLOPHOSPHAMIDE PLUS G-CSF COMPARED TO G-CSF IN STEADY-STATE

      Blood
    41. VOSO MT; HOHAUS S; PFORSICH M; MOOS M; MARTIN S; GOLDSCHMIDT H; HAAS R
      AUTOGRAFTING WITH SELECTED CD34(- RETAINED ENGRAFTMENT CAPABILITY ANDREDUCED TUMOR-CELL CONTENT() CELLS )

      Blood
    42. VOSO MT; HOHAUS S; MOOS M; HAAS R
      LACK OF T(14-18) POLYMERASE CHAIN REACTION-POSITIVE CELLS IN HIGHLY PURIFIED CD34(+) CELLS AND THEIR CD19 SUBSETS IN PATIENTS WITH FOLLICULAR LYMPHOMA

      Blood
    43. WANG SW; KRINKS M; MOOS M
      FRZB-1, AN ANTAGONIST OF WNT-1 AND WNT-8, DOES NOT BLOCK SIGNALING BYWNTS -3A, -5A, OR -11

      Biochemical and biophysical research communications
    44. MOOS M; MORRIS DI; ROBBINS J; APPEL L; SEAMON KB
      PURIFICATION OF BOVINE BRAIN ADENYLYL-CYCLASE WITH A NOVEL DERIVATIVEOF FORSKOLIN - EVIDENCE FOR A HIGH SPECIFIC ACTIVITY FORM OF THE ENZYME

      Preparative biochemistry & biotechnology
    45. HOLM J; HILLENBRAND R; STEUBER V; BARTSCH U; MOOS M; LUBBERT H; MONTAG D; SCHACHNER M
      STRUCTURAL FEATURES OF A CLOSE HOMOLOG OF L1 (CHL1) IN THE MOUSE - A NEW MEMBER OF THE L1 FAMILY OF NEURAL RECOGNITION MOLECULES

      European journal of neuroscience
    46. MUREA S; GOLDSCHMIDT H; HAHN U; PFORSICH M; MOOS M; HAAS R
      SUCCESSFUL COLLECTION AND TRANSPLANTATION OF PERIPHERAL-BLOOD STEM-CELLS IN CANCER-PATIENTS USING LARGE-VOLUME LEUKAPHERESES

      Journal of clinical apheresis
    47. BOCKER F; MOOS M; BOCKKOSTNER B
      PROFESSIONAL REHABILITATION IN THE PSYCHI ATRIC CLINIC

      Nervenheilkunde
    48. HAAS R; MOOS M; MOHLE R; DOHNER H; WITT B; GOLDSCHMIDT H; MUREA S; FLENTJE M; WANNENMACHER M; HUNSTEIN W
      HIGH-DOSE THERAPY WITH PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION IN LOW-GRADE NON-HODGKINS-LYMPHOMA

      Bone marrow transplantation
    49. CABOT GP; BENTZ M; SCHOLL C; MOOS M; FISCHER K; LICHTER P; DOHNER H
      HIGH-INCIDENCE OF A 2ND BCR-ABL FUSION IN CHRONIC MYELOID-LEUKEMIA REVEALED BY INTERPHASE CYTOGENETIC ANALYSIS ON FLOOD AND BONE-MARROW SMEARS

      Cancer genetics and cytogenetics
    50. SCHMIDT M; BIENEK C; RUMENAPP U; ZHANG CY; LUMMEN G; JAKOBS KH; JUST I; AKTORIES K; MOOS M; VONEICHELSTREIBER C
      A ROLE FOR RHO IN RECEPTOR-STIMULATED AND G-PROTEIN-STIMULATED PHOSPHOLIPASE-C - REDUCTION IN PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE BY CLOSTRIDIUM-DIFFICILE TOXIN-B

      Naunyn-Schmiedeberg's archives of pharmacology
    51. HOANG B; MOOS M; VUKICEVIC S; LUYTEN FP
      PRIMARY STRUCTURE AND TISSUE DISTRIBUTION OF FRZB, A NOVEL PROTEIN RELATED TO DROSOPHILA FRIZZLED, SUGGEST A ROLE IN SKELETAL MORPHOGENESIS

      The Journal of biological chemistry
    52. HAAS R; MUREA S; MOOS M; HOHAUS S; GOLDSCHMIDT H; HUNSTEIN W
      HIGH-DOSE THERAPY WITH PERIPHERAL-BLOOD STEM-CELL (PBSC) TRANSPLANTATION IN LOW-GRADE NON-HODGKINS-LYMPHOMAS (NHL)

      Blood
    53. MOOS M; SCHULZ R; MUREA S; HAAS R
      MINIMAL RESIDUAL DISEASE IN FOLLOW-UP SAMPLES OF PATIENTS WITH LOW-GRADE NON-HODGKINS-LYMPHOMA UNDERGOING HIGH-DOSE THERAPY WITH PERIPHERAL-BLOOD PROGENITOR-CELL SUPPORT - IS THERE AN IMPACT ON THE CLINICAL OUTCOME

      Blood
    54. WALLMEIER M; KALLMEYER C; KIEL K; MOOS M; HEGENBART U; HAAS R; GOLDSCHMIDT H; HUNSTEIN W
      PATIENTS WITH ADVANCED MULTIPLE-MYELOMA (MM) SHOW A LOW NUMBER OF CIRCULATING B-CELLS IN PERIPHERAL-BLOOD WITH SIGNIFICANT REDUCTION AFTER VAD CHEMOTHERAPY

      Blood
    55. KIEL K; CREMER F; ATZBERGER A; GOLDSCHMIDT H; MOOS M
      CD19(-CELLS AFTER HIGH-DOSE-THERAPY AND PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE-MYELOMA() CELLS CONTAIN ONLY A MINOR FRACTION OF MALIGNANT)

      Blood
    56. GOLDSCHMIDT H; HEGENBART U; CREMER F; KIEL K; WALLMEIER M; HOHAUS S; HAAS R; MOOS M
      PBPC MOBILIZATION IN MULTIPLE-MYELOMA - HIGH-DOSE CHEMOTHERAPY PLUS G-CSF VS 2 DIFFERENT DOSAGES OF G-CSF DURING STEADY-STATE

      Blood
    57. VOSO MT; HOHAUS S; BREHM M; MOOS M; HAAS R
      LACK OF T(14-18) PCR-POSITIVE CELLS IN HIGHLY PURIFIED CD34+ CELLS AND THEIR CD19 SUBSETS IN PATIENTS WITH FOLLICULAR LYMPHOMA

      Blood
    58. MOOS M; SCHMOHL D; FISCHER K; SCHLENK R; DIEHL D; HAAS R; DOHNER H
      PROSPECTIVE MONITORING OF MINIMAL RESIDUAL DISEASE BY POLYMERASE CHAIN-REACTION IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA EXPRESSING CBF-BETA-1MYH11 FUSION TRANSCRIPTS

      Blood
    59. HAAS R; MUREA S; GOLDSCHMIDT H; DOHNER H; MOOS M; WITT B; EUGENHART R; WANNENMACHER M; HUNSTEIN W
      HIGH-DOSE THERAPY WITH PERIPHERAL-BLOOD PROGENITOR-CELL SUPPORT IN PATIENTS WITH NON-HODGKINS-LYMPHOMA

      Stem cells
    60. GOLDSCHMIDT H; HEGENBART U; MOOS M; EUGENHART R; WANNENMACHER M; HAAS R; HUNSTEIN W
      SEQUENTIAL HIGH-DOSE TREATMENT WITH PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE-MYELOMA

      Stem cells
    61. MOOS M; SCHULZ R; CREMER F; SUCKER C; SCHMOHL D; DOHNER H; GOLDSCHMIDT H; HAAS R; HUNSTEIN W
      DETECTION OF MINIMAL RESIDUAL DISEASE BY POLYMERASE CHAIN-REACTION INB-CELL MALIGNANCIES

      Stem cells
    62. MOOS M; WANG SW; KRINKS M
      ANTI-DORSALIZING MORPHOGENETIC PROTEIN IS A NOVEL TGF-BETA HOMOLOG EXPRESSED IN THE SPEMANN ORGANIZER

      Development
    63. WANG SW; KRINKS M; MOOS M
      DNA-SEQUENCING FROM SINGLE PHAGE PLAQUES USING SOLID-PHASE MAGNETIC CAPTURE

      BioTechniques
    64. MOOS M; SCHULZ R; HAAS R
      THE SIGNIFICANCE OF POLYMERASE CHAIN-REACTION (PCR)-DETECTABLE T(14-18)-POSITIVE CELLS IN PATIENTS WITH NON-HODGKIN-LYMPHOMA (NHL) UNDERGOING SEQUENTIAL HIGH-DOSE THERAPY WITH PERIPHERAL-BLOOD PROGENITOR-CELL SUPPORT

      Experimental hematology
    65. MOOS M
      MODELS OF RISK ASSESSMENTS FOR BIOLOGICALS OR RELATED PRODUCTS IN THEEUROPEAN-UNION

      Revue scientifique et technique - Office international des epizooties
    66. HSIEH LS; MOOS M; LIN Y
      CHARACTERIZATION OF APPLE 18-KD AND 31-KD ALLERGENS BY MICROSEQUENCING AND EVALUATION OF THEIR CONTENT DURING STORAGE AND RIPENING

      Journal of allergy and clinical immunology
    67. HSIEH LS; MOOS M; LIN Y
      THE STUDY OF APPLE ALLERGENS

      Journal of allergy and clinical immunology
    68. MOOS M
      'END OF THE YEAR'

      The Midwest quarterly
    69. SCHMOHL D; DOHNER H; FISCHER K; SCHLENK R; HAAS R; MOOS M
      USE OF THE POLYMERASE CHAIN-REACTION FOR THE DETECTION OF CBF-BETA MYH11 FUSION TRANSCRIPTS IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA/

      Blood
    70. SUCKER C; KRAMER A; BETHAUSER H; ATZBERGER A; GOLDSCHMIDT H; MOOS M
      COMMON CLONAL TUMOR-ORIGIN IN A PATIENT WITH CONCOMITANT CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL) AND MULTIPLE-MYELOMA (MM)

      Blood
    71. HAAS R; MOOS M; KARCHER A; MOHLE R; WITT B; GOLDSCHMIDT H; FRUHAUF S; FLENTJE M; WANNENMACHER M; HUNSTEIN W
      SEQUENTIAL HIGH-DOSE THERAPY WITH PERIPHERAL-BLOOD PROGENITOR-CELL SUPPORT IN LOW-GRADE NON-HODGKINS-LYMPHOMA

      Journal of clinical oncology
    72. TAKAO M; OTRIN VR; ABRAMIC M; MOOS M; WOOTON JC; MCLENIGAN M; LEVINE AS; PROTIC M
      CLONING A CDNA-ENCODING A 127 KDA PROTEIN OF THE UV-DAMAGED DNA-BINDING COMPLEX

      Journal of cellular biochemistry
    73. DEGERMAN E; MOOS M; RASCON A; VASTA V; MEACCI E; SMITH CJ; LINDGREN S; ANDERSSON KE; BELFRAGE P; MANGANIELLO V
      SINGLE-STEP AFFINITY PURIFICATION, PARTIAL STRUCTURE AND PROPERTIES OF HUMAN PLATELET CGMP INHIBITED CAMP-PHOSPHODIESTERASE

      Biochimica et biophysica acta. Protein structure and molecular enzymology
    74. AKSAMIT RR; BACKLUND PS; MOOS M; CARYK T; GOMI T; OGAWA H; FUJIOKA M; CANTONI GL
      THE ROLE OF CYSTEINE-78 IN FLUOROSULFONYLBENZOYLADENOSINE INACTIVATION OF RAT-LIVER S-ADENOSYLHOMOCYSTEINE HYDROLASE

      The Journal of biological chemistry
    75. CHANG SC; HOANG B; THOMAS JT; VUKICEVIC S; LUYTEN FP; RYBA NJP; KOZAK CA; REDDI AH; MOOS M
      CARTILAGE-DERIVED MORPHOGENETIC PROTEINS - NEW MEMBERS OF THE TRANSFORMING GROWTH-FACTOR-BETA SUPERFAMILY PREDOMINANTLY EXPRESSED IN LONG BONES DURING HUMAN EMBRYONIC-DEVELOPMENT

      The Journal of biological chemistry
    76. GOLDSCHMIDT H; MOOS M; CREMER F; ATZBERGER A; WITT B; HAAS R; HUNSTEIN W
      ANTIGENIC PROFILE AND PCR ANALYSIS OF PERIPHERAL-BLOOD PROGENITOR-CELL AUTOGRAFTS IN MULTIPLE-MYELOMA

      Blood
    77. MOOS M; SCHULZ R; THEOBALD P; GOLDSCHMIDT H; HAAS R
      DETECTION OF T(14-18) POSITIVE CELLS USING THE POLYMERASE CHAIN-REACTION (PCR) IN PATIENTS WITH LOW AND INTERMEDIATE NON-HODGKIN-LYMPHOMA (NHL) UNDERGOING HIGH-DOSE THERAPY WITH PERIPHERAL-BLOOD PROGENITOR-CELL (PBPC) SUPPORT

      Blood
    78. BENTZ M; CABOT G; MOOS M; SPEICHER MR; GANSER A; LICHTER P; DOHNER H
      DETECTION OF CHIMERIC BCR-ABL GENES ON BONE-MARROW SAMPLES AND BLOOD SMEARS IN CHRONIC MYELOID AND ACUTE LYMPHOBLASTIC-LEUKEMIA BY IN-SITU HYBRIDIZATION

      Blood
    79. TAKAO M; ABRAMIC M; MOOS M; OTRIN VR; WOOTTON JC; MCLENIGAN M; LEVINE AS; PROTIC M
      A 127 KDA COMPONENT OF A UV-DAMAGED DNA-BINDING COMPLEX, WHICH IS DEFECTIVE IN SOME XERODERMA-PIGMENTOSUM GROUP-E PATIENTS, IS HOMOLOGOUS TO A SLIME-MOLD PROTEIN

      Nucleic acids research


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/08/20 alle ore 18:25:01